BRIEF-Izervay® (Avacincaptad Pegol Intravitreal Solution) Demonstrated Increased Probability Of Maintaining Driving Eligibility In Geographic Atrophy Patients

May 12 (Reuters) - Astellas Pharma Inc 4503.T:

  • IZERVAY® (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) DEMONSTRATED INCREASED PROBABILITY OF MAINTAINING DRIVING ELIGIBILITY IN GEOGRAPHIC ATROPHY PATIENTS

  • ASTELLAS PHARMA INC - AT 24 MONTHS, IZERVAY SHOWS 41% RELATIVE RISK REDUCTION VERSUS SHAM FOR LOSS OF DRIVING ELIGIBILITY

  • ASTELLAS PHARMA INC - GATHER2 DATA SHOW IZERVAY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS

Source text: ID:nPndMLj6a

Further company coverage: 4503.T


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.